Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Biologics IP - A Strategic Review: Profiling Patenting Activity of 13 Major Pharma-biotech Companies in the Area of Biologics - Research and Markets

Research and Markets
Posted on: 21 Sep 16

Research and Markets has announced the addition of the "Biologics IP - A Strategic Review (TechVision)" report to their offering.

This study provides a strategic overview of the patent activity of the 13 major pharma-biotech companies in the area of biologics. The biologics patent portfolios of these companies were analyzed and segmented by biologics type (e.g., peptides, antibodies, vaccines etc.) and therapeutic area for competitive benchmarking.

This study will help pharma-biotech companies understand the competitive landscape and the available white space from patenting perspective.

Key Topics Covered:

1. Executive Summary

2. Research Objective and Background

3. Research Scope and Methodology

4. Biologics Patent Portfolios of the Top 13 Major Pharma Companies

5. Overview of Biologics Patent Portfolio

Companies Mentioned

  • AbbVie
  • Amgen
  • AstraZeneca
  • Bayer HealthCare
  • Bristol-Myers Squibb
  • Eli Lilly
  • GSK
  • Merck
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sanofi

For more information about this report visit

Related Topics: Biopharmaceuticals

View source version on

Business Wire

Last updated on: 21/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.